Kyntra Bio cuts royalty financing cap from $125M to $65M; pays $42.6M upfront

KYNTRA BIO, INC.

Max payments under royalty financing cut from $125M to $65M; $42.6M accelerated payment brings total paid to $50M, full return of investor capital.
Remaining $15M cap paid from 50% of Astellas EVRENZO revenue (ex-Japan); after cap, Kyntra retains all royalties.
FibroGen Europe bankruptcy settled for ~$0.1M vs $19.2M obligations; combined liability reduction ~$80M.
Pro forma cash $53.1M as of June 30, 2026; cash runway into Q4 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.